Literature DB >> 23435559

Severity assessment of Japanese cedar pollinosis using the practical guideline for the management of allergic rhinitis in Japan and the allergic rhinitis and its impact on asthma guideline.

Minoru Gotoh1, Atsushi Yuta, Mitsuhiro Okano, Nobuo Ohta, Atsushi Matsubara, Kimihiro Okubo.   

Abstract

BACKGROUND: This study intended to assess the severity of Japanese cedar pollinosis using the Practical Guideline for the Management of Allergic Rhinitis in Japan (PG-MARJ) and the Allergic Rhinitis and its Impact on Asthma (ARIA) Guideline.
METHODS: An Internet questionnaire survey of patients with pollinosis was conducted in mid-May 2011 and responses were obtained from 3382 individuals who had potential symptoms of Japanese cedar pollinosis from February to early May 2011 and who had experienced such symptoms for at least two pollen seasons.
RESULTS: According to PG-MARJ, 23.5% of the respondents had severest rhinitis, 29.4% severe rhinitis, 31.3% moderate rhinitis, 13.8% mild rhinitis and 2.0% asymptomatic rhinitis. According to ARIA, 67.2% of them had moderate/severe persistent rhinitis, 23.8% moderate/severe intermittent rhinitis, 4.4% mild persistent rhinitis and 4.6% mild intermittent rhinitis.
CONCLUSIONS: Moderate to severe rhinitis was diagnosed in more than 80% of the respondents according to PG-MARJ, while moderate/severe rhinitis was diagnosed in more than 90% of the respondents according to ARIA. Most of the respondents suffered relatively severe pollinosis. More than 80% of the respondents had all the three major symptoms (i.e., sneezing, rhinorrhea and nasal blockage). Disagreement in the severity assessment between the two guidelines was noted in approximately 20% of the respondents.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23435559     DOI: 10.2332/allergolint.12-OA-0498

Source DB:  PubMed          Journal:  Allergol Int        ISSN: 1323-8930            Impact factor:   5.836


  2 in total

1.  Efficacy of a leukotriene receptor antagonist for pediatric cedar pollen allergy complicated by asthma.

Authors:  Shigemi Yoshihara; Yutaka Kikuchi; Mari Saitou; Susumu Yanagawa; Noriko Kanno; Hiroshi Igarashi; Hironobu Fukuda; Akiko Iimura; Toshio Abe; Yumi Yamada; Tamotsu Andou; Osamu Arisaka
Journal:  Exp Ther Med       Date:  2017-08-07       Impact factor: 2.447

2.  Circulating MMP-12 as Potential Biomarker in Evaluating Disease Severity and Efficacy of Sublingual Immunotherapy in Allergic Rhinitis.

Authors:  Yandan Zhou; Min Xu; Wei Gong; Xiaoming Kang; Renzhong Guo; Jie Wen; Dinggang Zhou; Manjing Wang; Dazhi Shi; Qiancheng Jing
Journal:  Mediators Inflamm       Date:  2022-06-12       Impact factor: 4.529

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.